NUVB Stock Recent News
NUVB LATEST HEADLINES
The FDA has placed a partial clinical hold on Nuvation Bio Inc's (NYSE: NUVB) Phase 1 dose-escalation study of NUV-422 in solid tumors. The company's Phase 1 trial began enrolling patients in December 2020 and, in recent months, was exploring higher doses to define a.
Benzinga 2022 Jun 27